Phase 2b challenge RCT in 45 evaluable adults: nasal BPZE1 vs placebo left 58% vs 33% free of B pertussis colonisation after challenge, not significant (p=0.091); 60% vs 25% in the adequate-inoculum sensitivity analysis (p=0.033).
RCTn = 53
Gbesemete et al. Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis